nodes	percent_of_prediction	percent_of_DWPC	metapath
Vigabatrin—GABBR1—uterine cervix—cervical cancer	0.0734	0.0908	CbGeAlD
Vigabatrin—GABBR1—decidua—cervical cancer	0.0699	0.0865	CbGeAlD
Vigabatrin—GABBR1—endometrium—cervical cancer	0.0664	0.0821	CbGeAlD
Vigabatrin—GABBR1—uterus—cervical cancer	0.0612	0.0757	CbGeAlD
Vigabatrin—SLC36A1—renal system—cervical cancer	0.0539	0.0667	CbGeAlD
Vigabatrin—ABAT—renal system—cervical cancer	0.0536	0.0663	CbGeAlD
Vigabatrin—GABBR1—female gonad—cervical cancer	0.05	0.0619	CbGeAlD
Vigabatrin—GABBR1—vagina—cervical cancer	0.0497	0.0615	CbGeAlD
Vigabatrin—SLC36A1—uterus—cervical cancer	0.048	0.0595	CbGeAlD
Vigabatrin—SLC36A1—female reproductive system—cervical cancer	0.0432	0.0534	CbGeAlD
Vigabatrin—SLC36A1—female gonad—cervical cancer	0.0393	0.0486	CbGeAlD
Vigabatrin—SLC36A1—vagina—cervical cancer	0.0391	0.0483	CbGeAlD
Vigabatrin—ABAT—female gonad—cervical cancer	0.0391	0.0483	CbGeAlD
Vigabatrin—ABAT—vagina—cervical cancer	0.0388	0.048	CbGeAlD
Vigabatrin—GABBR1—lymph node—cervical cancer	0.0322	0.0398	CbGeAlD
Vigabatrin—SLC36A1—lymph node—cervical cancer	0.0253	0.0313	CbGeAlD
Vigabatrin—ABAT—lymph node—cervical cancer	0.0251	0.0311	CbGeAlD
Vigabatrin—Dysmenorrhoea—Topotecan—cervical cancer	0.00964	0.0502	CcSEcCtD
Vigabatrin—Respiratory failure—Topotecan—cervical cancer	0.00893	0.0465	CcSEcCtD
Vigabatrin—Pulmonary embolism—Topotecan—cervical cancer	0.00877	0.0456	CcSEcCtD
Vigabatrin—Rash maculo-papular—Topotecan—cervical cancer	0.00797	0.0415	CcSEcCtD
Vigabatrin—Ear pain—Topotecan—cervical cancer	0.00746	0.0388	CcSEcCtD
Vigabatrin—Lethargy—Topotecan—cervical cancer	0.00649	0.0338	CcSEcCtD
Vigabatrin—Weight increased—Topotecan—cervical cancer	0.00501	0.0261	CcSEcCtD
Vigabatrin—Pneumonia—Topotecan—cervical cancer	0.00493	0.0257	CcSEcCtD
Vigabatrin—Infestation NOS—Topotecan—cervical cancer	0.0049	0.0255	CcSEcCtD
Vigabatrin—Infestation—Topotecan—cervical cancer	0.0049	0.0255	CcSEcCtD
Vigabatrin—Neuropathy peripheral—Topotecan—cervical cancer	0.00481	0.025	CcSEcCtD
Vigabatrin—Hepatobiliary disease—Topotecan—cervical cancer	0.00464	0.0241	CcSEcCtD
Vigabatrin—Hypoaesthesia—Topotecan—cervical cancer	0.00438	0.0228	CcSEcCtD
Vigabatrin—Malnutrition—Topotecan—cervical cancer	0.00383	0.02	CcSEcCtD
Vigabatrin—Back pain—Topotecan—cervical cancer	0.00371	0.0193	CcSEcCtD
Vigabatrin—Muscle spasms—Topotecan—cervical cancer	0.00368	0.0192	CcSEcCtD
Vigabatrin—Ill-defined disorder—Topotecan—cervical cancer	0.00356	0.0185	CcSEcCtD
Vigabatrin—Anaemia—Topotecan—cervical cancer	0.00354	0.0184	CcSEcCtD
Vigabatrin—Angioedema—Topotecan—cervical cancer	0.0035	0.0182	CcSEcCtD
Vigabatrin—Malaise—Topotecan—cervical cancer	0.00346	0.018	CcSEcCtD
Vigabatrin—Cough—Topotecan—cervical cancer	0.00334	0.0174	CcSEcCtD
Vigabatrin—Arthralgia—Topotecan—cervical cancer	0.00326	0.017	CcSEcCtD
Vigabatrin—Myalgia—Topotecan—cervical cancer	0.00326	0.017	CcSEcCtD
Vigabatrin—Chest pain—Topotecan—cervical cancer	0.00326	0.017	CcSEcCtD
Vigabatrin—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00324	0.0169	CcSEcCtD
Vigabatrin—Discomfort—Topotecan—cervical cancer	0.00322	0.0168	CcSEcCtD
Vigabatrin—Infection—Topotecan—cervical cancer	0.00311	0.0162	CcSEcCtD
Vigabatrin—Nervous system disorder—Topotecan—cervical cancer	0.00307	0.016	CcSEcCtD
Vigabatrin—Skin disorder—Topotecan—cervical cancer	0.00304	0.0158	CcSEcCtD
Vigabatrin—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00285	0.0148	CcSEcCtD
Vigabatrin—Paraesthesia—Topotecan—cervical cancer	0.00281	0.0146	CcSEcCtD
Vigabatrin—Dyspepsia—Topotecan—cervical cancer	0.00275	0.0143	CcSEcCtD
Vigabatrin—Decreased appetite—Topotecan—cervical cancer	0.00272	0.0142	CcSEcCtD
Vigabatrin—Gastrointestinal disorder—Topotecan—cervical cancer	0.0027	0.0141	CcSEcCtD
Vigabatrin—Fatigue—Topotecan—cervical cancer	0.0027	0.014	CcSEcCtD
Vigabatrin—Pain—Topotecan—cervical cancer	0.00267	0.0139	CcSEcCtD
Vigabatrin—Constipation—Topotecan—cervical cancer	0.00267	0.0139	CcSEcCtD
Vigabatrin—Feeling abnormal—Topotecan—cervical cancer	0.00258	0.0134	CcSEcCtD
Vigabatrin—Gastrointestinal pain—Topotecan—cervical cancer	0.00256	0.0133	CcSEcCtD
Vigabatrin—Urticaria—Topotecan—cervical cancer	0.00248	0.0129	CcSEcCtD
Vigabatrin—Body temperature increased—Topotecan—cervical cancer	0.00247	0.0129	CcSEcCtD
Vigabatrin—Abdominal pain—Topotecan—cervical cancer	0.00247	0.0129	CcSEcCtD
Vigabatrin—Hypersensitivity—Topotecan—cervical cancer	0.0023	0.012	CcSEcCtD
Vigabatrin—Asthenia—Topotecan—cervical cancer	0.00224	0.0117	CcSEcCtD
Vigabatrin—Pruritus—Topotecan—cervical cancer	0.00221	0.0115	CcSEcCtD
Vigabatrin—Diarrhoea—Topotecan—cervical cancer	0.00214	0.0111	CcSEcCtD
Vigabatrin—Dizziness—Topotecan—cervical cancer	0.00207	0.0108	CcSEcCtD
Vigabatrin—Vomiting—Topotecan—cervical cancer	0.00199	0.0104	CcSEcCtD
Vigabatrin—Rash—Topotecan—cervical cancer	0.00197	0.0103	CcSEcCtD
Vigabatrin—Dermatitis—Topotecan—cervical cancer	0.00197	0.0103	CcSEcCtD
Vigabatrin—Headache—Topotecan—cervical cancer	0.00196	0.0102	CcSEcCtD
Vigabatrin—Nausea—Topotecan—cervical cancer	0.00186	0.00967	CcSEcCtD
